QIAstat-Dx® Meningitis/Encephalitis Panel Performance Evaluation Study 001
NCT ID: NCT05092438
Last Updated: 2025-04-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
595 participants
OBSERVATIONAL
2021-10-08
2021-12-02
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Clinical Performance of QIAstat-Dx® Meningitis/Encephalitis (ME) Panel Plus
NCT06820060
Evolving Diagnostic Approaches to Undocumented Lymphocytic Meningitis and Meningoencephalitis
NCT07186881
A Comprehensive Clinical, Microbiological and Immunological Assessment of Patients With Suspected Post Treatment Lyme Disease Syndrome and Selected Control Populations
NCT00001539
Phase 1/2 Lyme Vaccine Study
NCT01504347
Evaluation, Treatment, and Follow-up of Patients With Lyme Disease
NCT00028080
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
RETROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Specimen that had not been centrifuged Adequate residual volume (≥400 μl)
Exclusion Criteria
* CSF obtained from an external ventricular drain or shunt source
* Lack of clear subject identification or label on residual banked CSF specimen
* Obvious physical damage of banked residual specimen
* Repeat specimens from the same subject
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
QIAGEN Gaithersburg, Inc
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Sarah Johnson
Role: STUDY_DIRECTOR
QIAGEN Gaithersburg, Inc
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Qiagen
Manchester, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SMF-DHF-18-0489-001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.